Four members of MS-13 face mandatory life sentences after a jury found them guilty in a string of crimes that included ...

The cable outlet known until Saturday morning as MSNBC has long been known for newsy hot takes. Now it’s putting some emphasis on reporters’ news breaks. Yes, that was MSNBC in September touting a ...

What’s in a name? On November 15, MSNBC will quickly find out. The cable-news outlet, slated to be spun out of NBCUniversal in the next few months and become part of a new publicly traded company ...

Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant ...

MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...

Multiple sclerosis (MS) is a chronic, disabling, inflammatory disease that damages your nerves. People with MS may live roughly seven years less than the general population, with an average life ...

OKLAHOMA CITY — The most common therapy for multiple sclerosis can increase the risk of a viral infection and the odds of a difficult recovery or even death from that infection. Now, scientists at the ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.

Smoking is an established risk factor for multiple sclerosis (MS). Smoking also worsens the course of disease for people who already have MS. MS is an inflammatory disease that involves the breakdown ...

MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Over 20 FDA-approved disease-modifying therapies exist, ...

In RRMS, the early course of the disease is characterised by intermittent relapses, and partial or complete recovery of function between exacerbations. The occurrence of relapses is a key measure of ...